Mann W A, Windler E, Beil F U, Greten H
Medizinische Kernklinik und Poliklinik, Universitäts-Krankenhaus Eppendorf, Hamburg, Germany.
Curr Opin Lipidol. 1995 Dec;6(6):354-9. doi: 10.1097/00041433-199512000-00004.
Recent trials on the efficacy of drugs and hormones in lowering cholesterol and correcting lipoprotein profiles are reviewed. Emphasis is placed on the risk-benefit ratio, which determines the clinical value of therapeutic regimens. Whereas 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitors have set a standard for treatment of hyperlipidaemia, the role of hormone replacement therapy in postmenopausal women in the prevention of coronary artery disease has more recently become better defined.
本文综述了近期关于药物和激素在降低胆固醇及纠正脂蛋白谱方面疗效的试验。重点在于风险效益比，它决定了治疗方案的临床价值。虽然3-羟基-3-甲基戊二酰辅酶A还原酶抑制剂已为高脂血症的治疗设定了标准，但激素替代疗法在绝经后女性预防冠状动脉疾病中的作用最近已变得更加明确。
